TRAX biotech catalysts & pipeline

FIRST TRACKS BIOTHERAPEUTICS INC · Data as of 2026-10-25

Upcoming catalysts

ANB101 — Initial data

Q4 2026

Currently evaluating potential development approach informed by clinical and translational evidence, as well as competitor registrational data in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) anticipated in Q4 2026 and early 2027, respectively

Source filing

ANB033 — Topline data

in Q1 2027

Cohort 2 of ANB033's Phase 1b trial in CeD, which is assessing mucosal healing in patients with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity through 12 weeks, is on track to complete enrollment imminently, with top-line data anticipated in Q1 2027.

Source filing

ANB101 — Initial data

early 2027

Currently evaluating potential development approach informed by clinical and translational evidence, as well as competitor registrational data in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) anticipated in Q4 2026 and early 2027, respectively

Source filing

ANB033 — Topline data

in Q3 2027

A Phase 1b cohort in eosinophilic esophagitis (EoE) is enrolling 50 patients with top-line data anticipated in Q3 2027.

Source filing

ANB033 — Conference presentation

in November

"We are deeply grateful to the patients, investigators and study teams who made this important milestone possible and look forward to presenting these results at ICDS in Melbourne in November."

Source filing

Explore the free biotech catalyst calendar